Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

BACKGROUND: In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly inhibited radiographic progression. In post hoc analyses, we evaluated changes in total PsA-modified Sharp/van der Heijde scores (SHS) across levels of composite index-defined disease a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip, Husni, M. Elaine, Kafka, Shelly, Chakravarty, Soumya D., Harrison, Diane D., Lo, Kim Hung, Xu, Stephen, Hsia, Elizabeth C., Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059340/
https://www.ncbi.nlm.nih.gov/pubmed/32143685
http://dx.doi.org/10.1186/s13075-020-2126-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059340/
https://www.ncbi.nlm.nih.gov/pubmed/32143685
http://dx.doi.org/10.1186/s13075-020-2126-1

Ejemplares similares